Harrow, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Harrow, Inc. (HROW) had Operating Lease, Weighted Average Discount Rate, Percent of 8.00% as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-03-02
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 8.00%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 8.08%.
- 2025-06-30: Operating Lease, Weighted Average Discount Rate, Percent 8.09%.
- 2025-03-31: Operating Lease, Weighted Average Discount Rate, Percent 8.04%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2025-12-31 | 8.00% 10-K · filed 2026-03-02 |
| 2025-09-30 | 8.08% 10-Q · filed 2025-11-10 |
| 2025-06-30 | 8.09% 10-Q · filed 2025-08-11 |
| 2025-03-31 | 8.04% 10-Q · filed 2025-05-08 |
| 2024-12-31 | 8.00% 10-K · filed 2026-03-02 |
| 2024-09-30 | 7.85% 10-Q · filed 2024-11-14 |
| 2024-06-30 | 6.60% 10-Q · filed 2024-08-07 |
| 2024-03-31 | 6.61% 10-Q · filed 2024-05-13 |
| 2023-12-31 | 6.60% 10-K · filed 2025-03-27 |
| 2023-09-30 | 6.60% 10-Q · filed 2023-11-13 |
| 2023-06-30 | 6.61% 10-Q · filed 2023-08-09 |
| 2023-03-31 | 6.61% 10-Q · filed 2023-05-11 |
| 2022-12-31 | 6.60% 10-K · filed 2024-03-19 |
| 2022-09-30 | 6.62% 10-Q · filed 2022-11-14 |
| 2022-06-30 | 6.61% 10-Q · filed 2022-08-09 |
| 2022-03-31 | 6.34% 10-Q · filed 2022-05-05 |
| 2021-12-31 | 6.30% 10-K · filed 2023-03-23 |
| 2020-12-31 | 6.30% 10-K · filed 2022-03-10 |
| 2019-12-31 | 6.30% 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |